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Potentiality of yeasts obtained as beer fermentation residue to be used as 1 
probiotics 2 
Abstract 3 
Beer is the most consumed alcoholic beverage worldwide and brewery is a growing industry. 4 
Biomass by-product of beer production is constituted by viable and non-viable flocculated 5 
yeasts which are discarded. To increase the value of this waste, the potential applications of 6 
the beer fermentation residue (BFR) as probiotic and bio-preservative were studied. Strains 7 
isolated from commercial brewing starters and BFRs were identified. The M6 BFR and its 8 
constituent strains, Saccharomyces cerevisiae CMUNLPY6.2 and Pichia kudriavzevii 9 
CMUNLPY6.1, proved to be the most resistant to gastrointestinal conditions in vitro. The 10 
cell-free supernatants obtained from micro-fermentations were capable to reduce Aspergillus 11 
flavus and Aspergillus parasiticus germination, two species well-known to produce the potent 12 
carcinogenic aflatoxin B1 (AFB1). A cytoprotective effect of the BFRs against AFB1 on 13 
HepG2 cells was observed. Brewing yeasts bound AFB1 in vitro, thus reducing the cell 14 
damage induced by the toxin. Throughout the study, yeasts grown in brewing wort showed 15 
better probiotic properties than the same yeasts grown in YPD broth. These results suggest 16 
that the wastes obtained from brewery would become a high-value probiotic product.  17 
Keywords: Brewing yeast; beer fermentation residue; aflatoxin B1 binding; probiotic. 18 
1. Introduction 19 
Beer is the most popular alcoholic beverages worldwide, and the third most consumed after 20 
water and tea. Global beer production has risen in the last decades, reaching 1.95 billion 21 
hectoliters in 2017 (Statista, 2018). Typically, the amount of brewing yeast biomass yield in 22 















Tavarela, 2010). This nutritive beer fermentation residue (BFR) is mostly discarded or utilized 24 
as feedstuff (Ferreira et al., 2010).  25 
Growing efforts are aimed to search probiotics as astrategy for human health promotion and 26 
disease prevention. According to the Food and Agriculture Organization and the World Health 27 
Organization, a probiotic is “a live microorganism which, when administered in adequate 28 
amounts, confers a health benefit to the host” (FAO/WHO, 2002). Lyophilized 29 
Saccharomyces cerevisiae var. boulardii is a probiotic yeast used worldwide for the 30 
prevention and treatment of diarrheal diseases (Czerucka, Piche & Rampal, 2007). Brewing 31 
yeasts, specifically species belonging to the Saccharomyces sensu stricto complex, have 32 
morphological and physiological similarity with S. boulardii (van der Aa Kühle & Jespersen, 33 
2003) and share cell wall compounds identified as possible responsible for S. boulardii 34 
probiotic effect (Ferreira et al., 2010). van der Aa Kühle, Skovgaard & Jespersen (2005) 35 
conclude that certain S. cerevisiae strains have potential as probiotics as they are able to 36 
tolerate low pH and bile and to reduce the intestinal pro-inflammatory response during 37 
bacterial infections. These reports reinforce our approach of studying brewing yeasts as 38 
potential probiotics. 39 
On the other hand, there is a concern about the effect o  mycotoxin consumption through 40 
contaminated food on human health. Mycotoxins are fungal carcinogenic metabolites 41 
produced mainly by Aspergillus, Penicillium and Fusarium genera (Pitt & Hocking, 2009). 42 
These fungi may develop in stored food and/or raw material, producing thermotolerant 43 
mycotoxins. As a strategy to face this problem, it was proposed that mycotoxins can be bound 44 
by certain yeasts, avoiding the toxin absorption in the gut and preventing disease (Fernandes 45 
Oliveira, Bovo, Corassin, Vincenzi Jager & Ravindranadha Reddy, 2013). The ability of dead 46 
brewing yeasts to bind mycotoxins such as aflatoxin B1 (AFB1), deoxynivalenol (DON), 47 















Bovo, Franco, Rosim, Barbalho & Fernandes de Oliveira, 2015). As an alternative strategy to 49 
counteract mycotoxins, the development of new bio-preservative supplements which prevent 50 
fungal germination in raw material, stored food and feedstuff are desirable. Armando et al. 51 
(2013) conclude that the strains S. cerevisiae RC008 and RC016 can be considered effective 52 
biocontrol agents against Aspergillus carbonarius and Fusarium graminearum. Also, these 53 
strains reduce OTA, ZEA and DON production in environmental conditions related to 54 
feedstuff storage. Previous reports support the use of y asts as biocontrol agents in food and 55 
beverage production (Shetty, Hald & Jespersen, 2007; Bleve, Grieco, Cozzi, Logrieco & 56 
Visconti, 2006). 57 
Abovementioned mentioned reports on different S. cerevisiae strains suggest that brewing 58 
starters could be potential probiotics. The aim of this work was to study the potential AFB1 59 
binding capability of yeasts obtained from BFRs andtheir effect on AFB1 cytotoxicity on a 60 
cell model. Additionally, antifungal effect of BFRs against aflatoxicogenic fungi was 61 
evaluated. 62 
2 Materials and methods 63 
2.1 Strains: origin and culture conditions 64 
Four brewing yeast consortia and eight yeasts isolated from these consortia were studied. 65 
Starters M4 and M6 were kindly provided by regional home brewers as BFRs. Consortia 66 
Safbrew S-33 and Safbrew WB-06 (Fermentis, Lesaffre, Marcq-en-Baroeul, France) are 67 
commercial freeze-dried brewing yeasts which were rconstituted in YPD broth (yeast extract 68 
10g/L, bacteriological peptone 20g/L, dextrose 20g/L).  69 
The yeasts were grown in three different conditions: a) 10.0 ml YPD broth at 30°C for 48 h; 70 
b) Laboratory Scale Brewing Wort (LSBW) cultures of 10.0 ml sterilized brewing wort, 71 















sterilized brewing wort, OG of 1040, at 18°C until a tenuation point, in order to harvest the 73 
yeast biomass residue, called BFR. The attenuation point was defined as the end of wort 74 
fermentation, obtaining the lowest sugar content for a specific yeast strain, measured by a 75 
hand-held refractometer Master 20T (Atago, Tokyo, Japan). The brewing wort was kindly 76 
provided by local home brewers and sterilized by autoclaving.  77 
Aflatoxicogenic strains of Aspergillus parasiticus CMUNLP7 (Gamba et al., 2015) and 78 
Aspergillus flavus CMUNLPI5 (formerly called A. flavus PJA [unpublished], kindly provided 79 
by Professor Vero [Universidad de la República, Uruguay] and designed according to the 80 
instructions of the Cathedra of Microbiology´s collection), obtained from collection of 81 
Cathedra of Microbiology (UNLP, Argentina), were grown on Potato Dextrose Agar (PDA, 82 
Britania, Buenos Aires, Argentina) slants for 7 days t 30°C to induce sporulation.  83 
2.2 Cell Cultures 84 
The human hepatocellular carcinoma cell line HepG2 was obtained from the Multidisciplinary 85 
Institute of Cell Biology (IMBICE, Buenos Aires, Argentina). These cells have shown to keep 86 
many parenchymal cell functions (Gutierrez-Ruiz, 1999). HepG2 cells were routinely 87 
maintained according to Gamba et al. (2015). Monolayers were prepared in 48-well tissue 88 
culture plates (Greiner Bio One, Frickenhausen, Germany) by seeding with a solution of 106 89 
CFU/mL (0.25 mL/well). Cells were used for bioassays ccording to the corresponding 90 
experimental protocol (Ou et al., 2012). 91 
2.3 Isolation and identification of yeasts strains 92 
Differentiated giant colonies were obtained as described by White & Zainasheff (2010), with 93 
minor modifications. An overnight YPD broth culture of each consortium was counted in 94 
Neubauer’s chamber and diluted in sterile PBS buffer (phosphate-buffered saline solution) to 95 















and incubated at 30 °C for 7 days. After incubation, colonies with different morphologies and 97 
textures were isolated in YGC agar until unique morph logy was observed. The isolated 98 
yeasts were maintained in YPD agar slants (yeast extract 10g/L, bacteriological peptone 20g/L, 99 
dextrose 20g/L, 20g/L agar agar) at 4°C. 100 
Yeast total DNA amplification from pure cultures was done by colony PCR (Mirhendi, Diba, 101 
Rezaei, Jalalizand, Hosseinpur & Khodadadi, 2006) using the primers ITS1 5’-102 
TCCGTAGGTGAACCTGCGG-3’and ITS4 5’-TCCTCCGCTTATTGATATGC-3’ (White, 103 
Bruns, Lee & Tailor, 1990), provided by Invitrogen company (Thermo Fisher Scientific Inc.®, 104 
MA USA). PCRs were carried out in a 20 µL final volume, using 1 µL of the DNA template, 105 
200 µmol/L of each dNTP, 0.25 µmol/L of each primer, 2.5 mmol/L of MgCl2, 10X buffer 106 
and 0.75 U of Taq DNA polymerase (Inbio Highway, Tandil, Argentina). PCR program 107 
consisted in a 4 min initial denaturalization step at 95°C, followed by 30 cycles of a 108 
denaturalization step at 95°C; an annealing step at 55°C for 30 s; an extension step at 72°C for 109 
1 min; and a final extension step at 72°C for 5 min. The amplification products were analyzed 110 
by electrophoresis on 0.8% p/v agarose gels before they were submitted for sequencing 111 
(Macrogen, Seoul, Korea). Data analysis was performed using BioEdit Sequence Alignment 112 
Editor for Windows and BLAST algorithm from NCBI database.  113 
2.4 Resistance to simulated gastrointestinal (GI) conditions  114 
The procedure was performed according to Minekus et al. (2014). Briefly, consortia and 115 
strains YPD cultures were harvested, washed twice wth physiologic solution (PS, NaCl 0.9 % 116 
p/v, pH 7.0), counted in Neubauer’s chamber and re-suspended to a final concentration of 106 117 
- 107 CFU/mL in Gastric Solution (3.0 g/L porcine pepsine [Sigma-Aldrich, St Louis, MO, 118 
USA] in sterile PS and pH adjusted to 2.5 with HCl 3 mol/L) pre-heated at 37°C and 119 















Intestinal Solution (1 g/L porcine pancreatin [Sigma-Aldrich] and 70 g/L bile salts (Britania 121 
S.A., CABA, Argentina) in sterile PS and pH adjusted o 8.0 with NaOH 1 mol/L) pre-heated 122 
at 37°C and incubated for 2 h. Aliquots of each suspen ion were taken before incubation, after 123 
the simulated gastric digestion and after the simulated intestinal passage. Samples were 124 
enumerated in YPD agar.  125 
2.5 Fungal germination reduction by cell-free supernatants (CFS) 126 
CFS were obtained by centrifugation and sterile filtration of brewing yeasts grown in YPD 127 
broth and in brewing wort (micro-fermentations). Aspergillus sp. strains were cultured on 128 
sloped PDA and suspensions of 104 spores/mL were obtained with a “spore solution” of 129 
0.01% w/v Sodium Lauryl Sulfate (SLS) and 1% w/w sodium chloride solution (Gamba et al., 130 
2015). A 96-well sterile microplate was inoculated with 190 µL of CFS plus 10 µL of the 131 
spore suspensions. As a positive control of fungal germination, wells were seeded with 10 µL 132 
of the spore suspension plus 190 µL of sterile YPD broth or brewing wort. As negative control 133 
wells were plated with sterile YPD broth or sterile br wing wort plus 10 µL of the sterile 134 
“spore solution”. The microplate was incubated at 30 °C for 48 h. The fungal germination was 135 
measured spectrophotometrically at 580 nm (Beckman DU 650, Palo Alto, USA). The rate of 136 
germination inhibition/reduction was calculated as follows:  137 
A = [1 - (B-D/C-D)] * 100 [1] 138 
Where A is the percentage of fungal germination reduction; B is the OD580 of the treatment; C 139 
and D are the OD580 of the positive and the negative controls, respectiv ly. 140 
2.6 Aflatoxin B1 (AFB1) solution preparation 141 
Crystalline AFB1 was purchased from Sigma Aldrich (St Louis, MO, USA). Stock solutions 142 















evaporating the acetonitrile/benzene mixture and reconstituting in methanol. AFB1 144 
concentrations were determined spectrophotometrically at 354 nm (ε354= 19,800 mol/l·cm) 145 
and stocks were stored at -20°C. Aqueous work solutions were prepared in sterile PBS. 146 
2.7 HepG2 cell damage induced by AFB1  147 
The cell damage induced by AFB1 in HepG2 cell line was assessed according to Gamba et al. 148 
(2015). Briefly, HepG2 cells were incubated with 108 CFU/mL yeasts re-suspended in 149 
DMEM (Dulbecco's Modified Eagle Medium, Merck, Darmstadt, Germany) with added AFB1 150 
and incubated at 37 °C in 5% CO2 atmosphere for 24 h. Positive (DMEM plus AFB1) and 151 
negative (DMEM without AFB1) controls were included. After incubation, cells supernatants 152 
were collected and lactate dehydrogenase (LDH) activity was quantified by LDH-P UV 153 
Unitest kit (Wiener Lab, Rosario, Argentina) using a spectrophotometer (Beckman DU 650). 154 
Data were analyzed according to the kit manufacturer instructions. 155 
2.8 AFB1 binding assay 156 
The AFB1 binding assay was performed according to Bueno, Casale, Pizzolitto, Salvano & 157 
Oliver (2007), with modifications. Yeasts were washed twice with sterile PBS, counted in 158 
Neubauer’s chamber, re-suspended in AFB1 solution to obtain suspensions containing 10
8 159 
CFU/mL and incubated at 30°C for 30 min with agitation (300 rpm). 160 
Then, cells were harvested by centrifugation and the supernatant containing unbound AFB1 161 
was collected and stored at -20◦C until quantification. Positive (PBS + mycotoxin) and 162 
negative (PBS + yeast) controls were included for all experiments. AFB1 was quantified 163 
following the manufacturer recommendations of Aflatoxin competitive direct ELISA test 164 















The mycotoxin bound by yeasts was calculated according to Campagnolo et al. (2015) as 166 
follows: 167 
A = [B - (C - D)] / B *100 [2] 168 
Where A is the percentage of AFB1 adsorbed by the yeasts, B is the concentration of AFB1 169 
added to buffer (300 ppb in PBS), C is AFB1 concentration in supernatants after incubation 170 
with the yeasts and D is the concentration of any interferences in the negative control. 171 
2.9 Simulated human GI digestion effect on AFB1/yeasts complex 172 
After AFB1 binding assay, yeasts were harvested by centrifugat on nd challenged to GI 173 
passage as described in section 2.4. To prevent washing out of the adsorbed AFB1, washes 174 
with PS between gastric and intestinal incubations were avoided. Immediately after each 175 
incubation, cells were centrifuged and aliquots of the supernatants were taken for 176 
quantification of the released AFB1. Controls were performed with yeasts incubated in PBS. 177 
The percentage of released mycotoxin by yeasts in each incubation step was calculated as 178 
follows: 179 
A = (B/C) * 100 [3] 180 
Where A is the percentage of AFB1 released by yeasts, B is the concentration of AFB1 181 
quantified in the supernatant after the incubation, and C is AFB1 concentration in PBS without 182 
yeasts. 183 
2.10 Statistical analysis 184 
Results were graphed by Sigmaplot 10.0® software. The results of three independent assays 185 















tested for significance by the analysis of variance (ANOVA) and Tukey test to determine 187 
significant effects at P < 0.05 by using Sigmaplot 10.0® software.  188 
3 Results and Discussion 189 
3.1 Isolates identification and human GI resistance  190 
Yeast strains used in this study were obtained from local brewers or commercial starters 191 
bought in local markets. All isolates where identified by sequencing of ITS1/ITS2 region as 192 
Saccharomyces cerevisiae, except for the CMUNLPY6.1 strain isolated from M6 starter, 193 
identified as Pichia kudriavzevii (Table 1). This is to be expected, since Saccharomyces sp. is 194 
the traditional brewing yeast, being S. cerevisiae mainly used for ale beer production (White 195 
& Zainasheff, 2010). Pichia kudriavzevii strains are usually isolated from other fermented 196 
products such as Tanzanian togwa (Hellstrom, Almgren, Carlsson, Svanberg & Andlid, 2012); 197 
Ghanaian fermented milk nunu (Akabanda et al., 2013); and fermented cereal gruel ogi198 
(Ogunremi, Sanni & Agrawal, 2015). 199 
Survival through the gastrointestinal conditions is de irable in the selection of probiotics, 200 
since viability plays a significant role in some beneficial properties (Diosma, Romanin, Rey-201 
Burusco, Londero & Garrote, 2013). Thus, the resistance of the microorganisms to the human 202 
gastrointestinal passage simulated in vitro was studied. As a standard method indicates 203 
(Minekus et al., 2014), we tested the yeasts grown in YPD broth. Table 1 shows that all the 204 
studied S. cerevisiae strains displayed a good resistance to GI conditions, with no significant 205 
reduction (P>0.05) in the counts for most strains, except for CMUNLPY4.1, CMUNLPY4.2 206 
and CMUNLPY33.1 (P<0.05). Among the last four, reductions were between 58% and 79% 207 
regarding the initial viable counts, showing an overall good tolerance of S. cerevisiae strains 208 
to GI passage. Our results agreed with previous reports of high resistance to the GI passage of 209 















Carrascosa & Requena, 2015). P. kudriavzevii was the only strain fully capable to survive the 211 
GI passage, even increasing its colony counts. This behavior was previously reported for 212 
different Pichia strains (Greppi et al., 2017; Chelliah, Rani Ramakrishnan, Prabhu & Antony, 213 
2016). Regarding consortia behavior, M6 showed the best resistance among the starters tested; 214 
and increased its counts after simulated passage to GI c nditions. This could be explained by 215 
P. kudriavzevii presence in this starter.  216 
S. cerevisiae strains, in particular S. cerevisiae var. boulardii, isolated from many fermented 217 
food and beverages, have been extendedly studied as potential probiotic yeasts (Tiago et al., 218 
2012; Shetty et al., 2007; van der Aa Kuhle t al., 2005). P. kudriavzevii, which has got the 219 
GRAS status (Kurtzman, Fell & Boekhorst, 2011), hasbeen isolated from different fermented 220 
and non-fermented beverages and foods, and identified as a potential probiotic (Greppi et al., 221 
2017; Chelliah et al., 2016; Diosma et al., 2013; Akabanda et al., 2013). To the best of our 222 
knowledge, there are no reports of probiotic Pi hia strains isolated from barley beer. In order 223 
to investigate both Saccharomyces and Pichia as potential probiotic yeasts, further studies 224 
were performed with the M6 starter and its strains (P. kudriavzevii CMUNLPY6.1 and S. 225 
cerevisiae CMUNLPY6.2) because of their good tolerance to human GI conditions. The same 226 
simulated human GI passage was performed with yeasts grown in brewing wort (at laboratory 227 
and micro-fermentation scale). BFR of P. kudriavzevii CMUNLPY6.1 displayed no 228 
significant reduction (P>0.05) in viable counts, showing a behavior similar to its YPD broth 229 
cultures at the end of GI passage (Table 2). All the yeasts cultured in LSBW showed a 230 
significant reduction (P<0.05) after GI passage compared to their initial counts, while YPD 231 
broth cultures did not (P<0.05). This could indicate  culture conditions dependence of the 232 
tolerance to GI passage, regardless of the yeast str in. However, M6 starter and P.233 
kudriavzevii CMUNLPY6.1 showed no differences (P>0.05) in viable counts between the 234 















of S. cerevisiae CMUNLPY6.2 significantly reduced (P<0.05) its counts compared to the 236 
other culture conditions.  237 
BFRs of M6 starter and S. cerevisiae CMUNLPY6.2 significantly decreased (P<0.05) its 238 
viable counts after the GI passage. This increased sensitivity to GI conditions of brewing wort 239 
cultures compared to YPD broth cultures may be explained by extensive changes in the 240 
composition and structure of the cell wall induced by fermentation in a complex and sugar 241 
concentrated medium such as brewing wort (Boulton, 2017). The longer and stressful 242 
exposure to micro-fermentation conditions, which include depletion of O2 (affecting sterols 243 
membrane composition) and lowering of pH, added to the osmotic stress of brewing wort 244 
(Boulton, 2017). The effects on the reduction of the viable counts after GI passage were no 245 
significant (P>0.05) for P. kudriavzevii CMUNLPY6.1 (Table 2). The ability of P. 246 
kudriavzevii CMUNLPY6.1 cultured in YPD broth to grow under the stressful GI conditions 247 
could explain this result as an overall higher resistance of this strain, regardless of the culture 248 
conditions. 249 
 250 
3.2 Fungal germination reduction by CFSs obtained from brewing yeasts 251 
A. parasiticus and A. flavus are two species capable to produce AFB1, a mycotoxin with 252 
deleterious effects on human health including aflatoxicosis, immunosuppression and liver 253 
cancer (Kew, 2013; Pitt & Hocking, 2009). Fungal germination inhibition and the consequent 254 
prevention of the aflatoxin production is one possible strategy to reduce their impact. Thus, 255 
the capability of CFSs obtained from brewing yeasts to reduce these fungi germination was 256 
studied (Fig. 1). The CFS obtained from micro-fermentation culture conditions showed 257 
significant reduction (P<0.05) of the fungal germinat on, whereas the CFS obtained from the 258 















CFSs obtained by micro-fermentation. A. parasiticus CMUNLP7 was inhibited by M6 starter 260 
and S. cerevisiae CMUNLPY6.2 but not by P. kudriavzevii CMUNLPY6.1. 261 
3.3 Brewing yeasts effect on HepG2 cell damage induced by AFB1 262 
Aflatoxin deleterious effects on health occur due to its accumulation in the liver. Thus, human 263 
hepatocarcinoma cell line HepG2 has been proposed as a model for aflatoxin studies (Mc 264 
Kean et al., 2006). Cell damage, associated with the level of lactate dehydrogenase released 265 
by eukaryotic cell wall permeabilization, can be indirectly quantified as LDH activity 266 
(Legrand et al., 1992). Gamba et al. (2015) reported that different amounts of AFB1 induce 267 
dose-dependent damage in HepG2 cells. Brewing yeasts’ protective effect upon HepG2 cells 268 
exposed to 500 ng/mL AFB1 suspension was demonstrated. Moreover, the presenc of 269 
brewing yeasts recovers the basal LDH activity of non-challenged HepG2 cells (Fig. 2). This 270 
is the first report about the protective effect of brewing yeasts on HepG2 cells against AFB1 271 
cytotoxic effect.  272 
3.4 AFB1 binding by brewing yeasts 273 
The cytoprotective effect observed on HepG2 cells could be explained by 274 
reduction/elimination of the aflatoxin available to interact with cells. Our results indicate that 275 
BFRs (with no pre-treatment) and LSBW cultures bound between 80% and 90% of the AFB1 276 
present in the medium, while YPD broth-cultured yeasts barely attached 8% to 20% (Table 3). 277 
Previous reports support the key role of yeast cell wa  in its detoxifying capability, since the 278 
mechanism involves the molecule adsorption on the yeast surface (Bueno et al., 2007; 279 
Yiannikouris et al., 2004). Consequently, differences in the structure and composition of the 280 
cell wall are related with yeasts competence to bind mycotoxins. Our hypothesis is that 281 
growing in a complex medium such as brewing wort induces an extensive rearrangement in 282 
the yeasts cell wall (Boulton, 2017), which enhances th ir mycotoxin binding capability. This 283 















detoxifying agents. Previous reports demonstrated that dried brewing yeasts and brewing 285 
yeasts-based products bind AFB1 (Gonçalves, Rosim, Fernandes de Oliveira & Corassin, 286 
2015; Campagnolo et al., 2015; Bovo et al., 2014). While these authors used dried yeasts, in 287 
this report BFRs without any pre-treatment were tested and found to bind AFB1. 288 
3.5 BFR yeasts/AFB1 complex stability through GI passage 289 
We evaluated the stability of the BFR/AFB1 complex during the GI passage. According to 290 
Moslehi-Jenabian, Lindegaard Pedersen & Jespersen (2010), the S. cerevisiae-AFB1 complex 291 
is stable during the passage through an in vitro GI model and the treatment enhanced yeast 292 
binding competence up to 78% of total added toxin. After gastric and intestinal incubations, 293 
remaining AFB1 in supernatants (de-attached) was measured. Both set of conditions (gastric 294 
and intestinal) affected the yeast/mycotoxin complex. According to our results, P. 295 
kudriavzevii CMUNLPY6.1 and S. cerevisiae CMUNLPY6.2 lost about a 25% of the bound 296 
mycotoxin (Table 4), remaining 54% of the initial added AFB1 strongly attached. For the M6 297 
starter, this percentage significantly (P<0.05) increased to 56%. This suggests that most of the 298 
initial mycotoxin ingested would not be potentially absorbed in the gastrointestinal tract but 299 
excreted together with the yeasts in feces. 300 
4. Conclusions  301 
In order to improve BFR value, the potential applications of this waste as probiotic and bio-302 
preservative agent were studied. We demonstrated that M6 brewing starter and P. kudriavzevii 303 
CMUNLPY6.1 and S. cerevisiae CMUNLPY6.2 isolated from this starter can tolerate 304 
gastrointestinal conditions simulated in vitro. The micro-fermentation supernatants showed 305 
fungal germination reduction of the aflatoxin producers’ A. parasiticus and A. flavus. 306 
Moreover, BFRs were able to bind AFB1 and decreased the cytotoxic effect of AFB1 on 307 















elimination of more than the 50% of the initial AFB1 present in the medium. Further in vivo 309 
studies are required to corroborate these results. Thi  is the first report of BFR (without any 310 
pre-treatment) with in vitro GI resistance and cytoprotective effect against AFB1 on cell 311 
model. Food supplemented with BFR would be an interesting application, and these results 312 
reinforces this course of investigation. 313 
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P. kudriavzevii CMUNLPY6.1 12.9 ± 0.1 a,A 12.2 ± 0.3 b,A 25.1 ± 0.4 A 
S. cerevisiae CMUNLPY6.2 13.1 ± 0.1 a,A 12.8 ± 0.2 a,B 25.9 ± 0.3 B 
M6 starter 12.1 ± 0.1 a,B 10.7 ± 0.1 b,C 22.8 ± 0.2 C 
 
*BFR (beer fermentation residue). **AFB1 was determined by ELISA kit Veratox
® 
(Neogen Corporation, St. Louis, MO, USA), according to the manufacturer 
instructions. Ϯ Rate of de-attached aflatoxin was calculated with regard to the added 
AFB1 in the binding assay buffer (300 ppb). Data are means ± standard deviations 
from three experiments in duplicate. Means within te same row with different 
lowercase letters are significantly different (P < 0.05). Means within the same column 













Table 1. Resistance of brewing starters and isolated yeasts to in vitro simulated human 















M6 starter 7.12 ± 0.10 a 7.11 ± 0.07 a 7.24 ± 0.09 a,A 
 
M4 starter 7.71 ± 0.01 a 7.73 ± 0.05 a 7.19 ± 0.04 a,ABC 
Safbrew S-33 6.85 ± 0.07 a 7.27 ± 0.10 b 6.70 ± 0.22 a,C 
Safbrew WB-06 7.21 ± 0.11 a 7.26 ± 0.08 a 7.06 ± 0.08 a,ABCD 
CMUNLPY6.1 7.08 ± 0.05 a 6.97 ± 0.08
 a 7.22 ± 0.01 a,AB P. kudriavzevii 
CMUNLPY6.2 7.21 ± 0.03 ab  7.41 ± 0.04 a 6.78 ± 0.09 b,BCD S. cerevisiae 
CMUNLPY4.1 7.91 ± 0.09 a 7.86 ± 0.01 a 7.23 ± 0.06 b,AB S. cerevisiae 
CMUNLPY 4.2 7.67 ± 0.02 a 7.75 ± 0.03 a 7.04 ± 0.03 b,ABCD S. cerevisiae 
CMUNLPY 33.1   7.29 ± 0.00 a 7.31 ± 0.01 a 6.90 ± 0.17 b,ABCD S. cerevisiae 
CMUNLPY 33.2  7.18 ± 0.07 a 7.26 ± 0.06 a 6.84 ± 0.08 a,ABCD S. cerevisiae 
CMUNLPY WB.1 7.08 ± 0.14 a 7.14 ± 0.04 a 6.52 ± 0.12 a,D S. cerevisiae 
CMUNLPY WB.2 7.09 ± 0.12 a 7.01 ± 0.04 a 6.85 ± 0.27 a,ABCD S. cerevisiae 
 
M6 and M4 consortia are harvested for re-use brewing yeasts kindly provided by local 
home brewers. Safbrew S-33 and Safbrew WB-06 (Fermentis, Lesaffre, France) 
consortia are commercial freeze-dried brewing yeasts which were reconstituted in YPD 
broth for the assay. CMUNLPY6.1 and CMUNLPY6.2 were isolated from M6 starter. 
CMUNLPY4.1 and CMUNLPY4.2 were isolated from M4 starter. CMUNLPY33.1 and 
CMUNLPY33.2 were isolated from Safbrew S-33 starter. CMUNLPYWB.1 and 
CMUNLPYWB.2 were isolated from Safbrew WB-06. Data re means ± standard 
deviations from three experiments in duplicate. 
Data expressed as means ± standard deviations from three experiments in duplicate. 
Means within the same row with different lowercase letters are significantly different (P 
< 0.05). Means within the same column with different capital letters are significantly 













Table 2. Beer fermentation residue’s (BRF) resistance to in vitro simulated human 





After simulated gastric 
digestion 
(log CFU/mL) 
After simulated intestinal 
passage 
(log CFU/mL) 
P. kudriavzevii LSBW* 7.69 ± 0.02 a 7.24 ± 0.01 b 6.88 ± 0.07 b,AB 
P. kudriavzevii BFR** 7.15 ± 0.00 a 6.70 ± 0.06 a 6.29 ± 0.14 a,AB 
P. kudriavzevii YPDϮ 7.08 ± 0.05 a 6.97 ± 0.08 a 7.22 ± 0.01 a,A 
S. cerevisiae LSBW* 7.62 ± 0.01 a 7.19 ± 0.14 b 6.61 ± 0.12 b,AB 
S. cerevisiae BFR** 8.05 ± 0.05 a 6.18 ± 0.14 b 4.64 ± 0.65 b,B 
S. cerevisiae YPDϮ 7.21 ± 0.03 ab 7.41 ± 0.04 a 6.78 ± 0.09 b,AB 
M6 starter LSBW* 7.59 ± 0.04 a 7.34 ± 0.09 b 7.18 ± 0.11 b,AB 
M6 starter BFR** 7.37 ± 0.16 a 6.70 ± 0.36 b 6.41 ± 0.15 b,AB 
M6 starter YPDϮ 7.12 ± 0.10 a 7.11 ± 0.07 a 7.24 ± 0.09 a,A 
 
* LSBW, stands for Laboratory Scale Brewing Wort culture, 10.0 mL agitated brewing 
wort cultures at 30°C for 72 h, as described in section 2.1. ** BFR, stands for Brewing 
Fermentation Residue, 700.0 mL brewing wort cultures at 18°C without agitation, till 
attenuation point was reached (approximately 10 days), as described in section 2.1. Ϯ 
YPD broth culture, 10.0 mL agitated YPD broth cultures at 30°C for 48 h, as described 
in section 2.1.  
Data expressed as means ± standard deviations from three experiments in duplicate. 
Means within the same row with different lowercase letters are significantly different (P 
< 0.05). Means within the same column with different capital letters are significantly 


















YPD* broth cultures (%) LSBW cultures** (%) BFR*** (%) 
P. kudriavzevii 
CMUNLPY6.1 
4.7 ± 2.4 a 83.8 ± 0.0 b 79.2 ± 1.4 c 
S. cerevisiae 
CMUNLPY6.2 
7.7 ± 0.9 a 83.8 ± 0.0 b 79.0 ± 0.0 c 
M6 starter 7.8 ± 4.8 a 83.7 ± 0.1 b 79.1 ± 0.1 c 
 
Ϯ Aflatoxin B1 was determined in supernatants by ELISA kit Veratox
® (Neogen 
Corporation, St. Louis, MO, USA), according to the manufacturer instructions. Data are 
means ± standard deviations from three experiments in duplicate. Lowercase letters 
indicate statistically significant difference (p < 0.05) between different media for the 
same strain. * YPD (broth culture): 10 mL agitated YPD broth cultures at 30°C for 48 h, 
as described in section 2.1. ** LSBW (Laboratory Scale Brewing Wort culture): 10 mL 
agitated brewing wort cultures at 30°C for 72 h, as de cribed in section 2.1. *** BFR 
(Brewing Fermentation Residue): 700 mL brewing wort cul ures at 18°C without 
agitation, till attenuation point was reached (approximately 10 days), as described in 
















Fig 2. Protective effect of brewing yeasts against cytotoxicity induced by AFB1 on 
HepG2 cells. LDH activity was determined by Wiener Lab® (Rosario, Argentina) 
according to the manufacturer instructions. A: P. kudriavzevii CMUNLPY6.1 YPD 
culture+ AFB1 500 ppb. B: S. cerevisiae CMUNLPY6.2 YPD culture + AFB1 500 ppb. 
C: M6 starter YPD culture + AFB1 500 ppb. D: P. kudriavzevii CMUNLPY6.1 brewing 
wort culture+ AFB1 500 ppb. E: S. cerevisiae CMUNLPY6.2 brewing wort culture + 
AFB1 500 ppb. F: M6 starter brewing wort culture + AFB1 500 ppb. C- (negative 
control): DMEM without AFB1. C+ (positive control): AFB1 500 ppb in DMEM. Bars 
are means ± standard deviations from three experiments in triplicate. * Mean values are 





















Fig 1. Fungal germination reduction by cell-free supernata ts obtained from brewing 
yeasts. Grey bars: culture supernatants obtained from micro-fermentations in brewing 
wort. Black bars: culture supernatants obtained from YPD broth cultures. A: A. 
parasiticus CMUNLP7/M6 starter. B: A. parasiticus CMUNLP7/P. kudriavzevii 
CMUNLPY6.1. C: A. parasiticus CMUNLP7/S. cerevisiae CMUNLPY6.2. D: A. flavus 
CMUNLPI5/M6 starter. E: A. flavus CMUNLPI5/P. kudriavzevii CMUNLPY6.1. F: A. 
flavus CMUNLPI5/S. cerevisiae CMUNLPY6.2. Bars are means ± standard deviations 
from three experiments in quadruplicate. Symbols (*, Ϯ) show significantly differences 






















• Yeasts obtained as beer fermentation residue show potential probiotic activity. 
• The beer fermentation residue protects HepG2 cells from aflatoxin B1 
cytotoxicity. 
• Beer fermentation residue binds aflatoxin B1 better than YPD cultured yeast. 
 
 
